FMI - Foundation Medicine, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters9 months ago

    With new blood test, Roche dives deeper into personal cancer care

    Swiss drugmaker Roche upped its bet on personalised cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumours from a patient's blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient's tumour.

  • Incyte, Foundation Medicine Partner for Companion Diagnostics
    Zacks9 months ago

    Incyte, Foundation Medicine Partner for Companion Diagnostics

    Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.

  • Business Wire10 months ago

    Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy

    Foundation Medicine, today announced the publication of the results of a large study demonstrating that its novel, investigational assay to measure blood tumor mutational burden (bTMB) can help predict response to the anti-PD-L1 immunotherapy, atezolizumab, (TECENTRIQ®) in patients with previously treated non-small cell lung cancer (NSCLC). The study, published in the journal Nature Medicine, was the result of a collaboration between Foundation Medicine and Genentech, a member of the Roche Group, and demonstrates the potential of bTMB to expand precision oncology approaches for patients with advanced cancers, including metastatic lung cancer. In addition, these results show that bTMB may be an independent predictor of clinical benefit, regardless of PD-L1 expression as assessed by immunohistochemistry.

  • GlobeNewswire11 months ago

    Roche Purchases Shares in Tender Offer for FMI

    OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.

  • ACCESSWIRE11 months ago

    Breakfast Technical Briefing on TrovaGene and Three Other Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on TROV sign up now at draws investors' attention to the Medical Laboratories and Research category, which includes companies that focus on performing various tests on patients that give them information on patients' health. Lined up for review are the following equities: Foundation Medicine Inc. (NASDAQ: FMI), NeoGenomics Inc. (NASDAQ: NEO), Neuronetics Inc. (NASDAQ: STIM), and TrovaGene Inc. (NASDAQ: TROV).

  • Business Wire11 months ago

    Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit

    Foundation Medicine, Inc. and Guardant Health, Inc. announced an agreement to settle a patent infringement lawsuit brought by Foundation Medicine against Guardant concerning U.S.

  • 3 Best Biotech Acquisitions of 2018 (So Far)
    Motley Fool11 months ago

    3 Best Biotech Acquisitions of 2018 (So Far)

    There were bigger biotech deals than these this year, but arguably none better.

  • GlobeNewswirelast year

    Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash

    OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of 18 June 2018 among Foundation Medicine, Inc., Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, and 062018 Merger Subsidiary, Inc., a wholly owned subsidiary of Roche Holdings, Inc. The tender offer period will expire at 12am midnight, Eastern Time, at the end of the day on 30 July 2018, unless the offer is extended.

  • Motley Foollast year

    What Roche's Acquisition of Foundation Medicine Means for Investors

    Roche makes a big bet on precision oncology.

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zackslast year

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Motley Foollast year

    Big Biotech Stock Pops and Drops This Week

    Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.

  • Company News For Jun 20, 2018
    Zackslast year

    Company News For Jun 20, 2018

    Companies in the news are: T,FMI,COTV,SRPT

  • ACCESSWIRElast year

    Today’s Research Reports on Stocks to Watch: Foundation Medicine and Solid Biosciences

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Shares of Foundation Medicine exploded on Tuesday after announcing that it has entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI`s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share. Shares of Solid Biosciences also broke out after announcing that the FDA has lifted a clinical hold on the company's phase I/II trial, IGNITE DMD, for its experimental candidate, SGT-001. Foundation Medicine, Inc. shares closed up 28.46% on Tuesday, with about 6.3 million shares traded compared to an average trading volume of about 409,00 shares.

  • Roche to Buy Rest of Foundation Medicine for $2.4 billion
    Zackslast year

    Roche to Buy Rest of Foundation Medicine for $2.4 billion

    Roche inks a deal with Foundation Medicine to acquire the remaining shares of Foundation Medicine, not already owned by it for a total consideration of $2.4 billion.